• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.

作者信息

Volmar K E, Hutchins G M

机构信息

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.

出版信息

Arch Pathol Lab Med. 2001 Dec;125(12):1555-61. doi: 10.5858/2001-125-1555-AAMFPV.

DOI:10.5858/2001-125-1555-AAMFPV
PMID:11735689
Abstract

CONTEXT

Few published studies of the pathology of fenfluramine-phentermine (fen-phen) valvulopathy, described by Connolly and colleagues in 1997, have appeared.

OBJECTIVES

To define temporal changes in the morphology of the stuck-on plaques and to determine whether the plaques progress or regress after cessation of fen-phen.

METHODS

The available clinical information and pathology material from 35 aortic valves (AVs) and 43 mitral valves (MVs) from 64 patients were reviewed.

RESULTS

The valves fell into 3 groups: 17 AVs and 28 MVs had fen-phen lesions only, 2 AVs and 7 MVs had fen-phen changes associated with other valve diseases, and 16 AVs and 8 MVs had no fen-phen changes. Fenfluramine-phentermine-attributable dysfunction was regurgitation in all instances. Typical plaques showed proliferation of myofibroblastic cells with myxoid stroma. Small vascular channels and slight lymphocytic accumulations were often present. Deeper parts of some plaques had dense fibroelastic tissue underlying typical plaque.

CONCLUSIONS

Considerable individual variation in the time course of anorectic agent use and the severity of fen-phen valvulopathy was observed. Possible plaque regression could not be assessed from this study. The observations suggest that in some patients fen-phen-induced plaques may continue to have surface proliferation despite drug withdrawal.

摘要

相似文献

1
Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.
Arch Pathol Lab Med. 2001 Dec;125(12):1555-61. doi: 10.5858/2001-125-1555-AAMFPV.
2
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.服用芬氟拉明-苯丙胺复方制剂或右芬氟拉明的患者中二尖瓣和/或主动脉瓣反流的超声心动图患病率。
Am J Cardiol. 1999 Dec 1;84(11):1335-8. doi: 10.1016/s0002-9149(99)00567-6.
3
Histologic changes in three explanted native cardiac valves following use of fenfluramines.使用芬氟拉明后三个移植的天然心脏瓣膜的组织学变化。
Cardiovasc Pathol. 1999 Sep-Oct;8(5):245-53. doi: 10.1016/s1054-8807(99)00019-8.
4
Regression and progression of valvulopathy associated with fenfluramine and phentermine.与芬氟拉明和苯丁胺相关的瓣膜病的消退和进展
Ann Intern Med. 2002 Mar 19;136(6):489. doi: 10.7326/0003-4819-136-6-200203190-00018.
5
Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.服用“芬芬”的患者中有一半出现无症状性二尖瓣和主动脉瓣疾病。
Arch Intern Med. 1998 Jan 12;158(1):102. doi: 10.1001/archinte.158.1.102.
6
Valvular heart disease associated with fenfluramine-phentermine.与芬氟拉明-苯丙胺相关的心脏瓣膜病。
N Engl J Med. 1997 Aug 28;337(9):581-8. doi: 10.1056/NEJM199708283370901.
7
The longitudinal effects of fenfluramine-phentermine use.使用芬氟拉明-苯丙胺的纵向影响。
Angiology. 2007 Jun-Jul;58(3):353-9. doi: 10.1177/0003319707302496.
8
Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy.使用芬氟拉明对患有瓣膜病的芬-芬(fen-phen)患者瓣膜性心脏病严重程度的剂量效应。
Int J Obes Relat Metab Disord. 1999 Sep;23(9):926-8. doi: 10.1038/sj.ijo.0801020.
9
Silver lining to the cloud over anorexogen-related cardiac valvulopathy?与厌食剂相关的心脏瓣膜病阴霾中的一线希望?
Ann Intern Med. 2001 Feb 20;134(4):335-7. doi: 10.7326/0003-4819-134-4-200102200-00018.
10
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.一项基于人群的食欲抑制药物与心脏瓣膜反流风险的研究。
N Engl J Med. 1998 Sep 10;339(11):719-24. doi: 10.1056/NEJM199809103391102.

引用本文的文献

1
Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation.二尖瓣中血清素转运体活性降低导致退行性二尖瓣反流进展。
Sci Transl Med. 2023 Jan 4;15(677):eadc9606. doi: 10.1126/scitranslmed.adc9606.
2
Key Characteristics of Cardiovascular Toxicants.心血管毒物的主要特征。
Environ Health Perspect. 2021 Sep;129(9):95001. doi: 10.1289/EHP9321. Epub 2021 Sep 24.
3
Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.药物相关性心脏瓣膜病与 5-羟色胺相关通路:荟萃分析
Heart. 2019 Aug;105(15):1140-1148. doi: 10.1136/heartjnl-2018-314403. Epub 2019 May 25.
4
The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.索尔福德肺部研究:临床试验中针对慢性阻塞性肺疾病和哮喘的一种开创性的比较疗效研究方法。
Pragmat Obs Res. 2017 Sep 20;8:175-181. doi: 10.2147/POR.S144157. eCollection 2017.
5
Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.芬氟拉明会破坏二尖瓣间质细胞对血清素的反应。
Am J Pathol. 2009 Sep;175(3):988-97. doi: 10.2353/ajpath.2009.081101. Epub 2009 Aug 13.
6
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.与芬氟拉明使用相关的瓣膜反流及手术:对5743例个体的分析
BMC Med. 2008 Nov 6;6:34. doi: 10.1186/1741-7015-6-34.
7
Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.肺动脉高压、甲状腺功能亢进与芬氟拉明:一例病例报告及文献综述
MedGenMed. 2006 Nov 8;8(4):29.
8
Risk of valvular heart disease associated with use of fenfluramine.与使用芬氟拉明相关的心脏瓣膜病风险。
BMC Cardiovasc Disord. 2003 Jun 11;3:5. doi: 10.1186/1471-2261-3-5.